aTyr Pharma [LIFE] vs Capricor [CAPR] Detailed Stock Comparison

aTyr Pharma Inc

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: aTyr Pharma Inc wins in 13 metrics, Capricor Therapeutics Inc. wins in 2 metrics, with 0 ties. aTyr Pharma Inc appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric aTyr Pharma Inc Capricor Therapeutics Inc. Better
P/E Ratio (TTM) 14.35 -15.61 aTyr Pharma Inc
Price-to-Book Ratio -42.41 6.62 Capricor Therapeutics Inc.
Debt-to-Equity Ratio 0.62 4.75 aTyr Pharma Inc
PEG Ratio 8.46 -0.05 aTyr Pharma Inc
EV/EBITDA 16.72 -16.23 aTyr Pharma Inc
Profit Margin (TTM) 18.36% 0.00% aTyr Pharma Inc
Operating Margin (TTM) 22.23% 0.00% aTyr Pharma Inc
EBITDA Margin (TTM) 22.23% N/A N/A
Return on Equity 21.03% -46.56% aTyr Pharma Inc
Return on Assets (TTM) 10.00% -25.68% aTyr Pharma Inc
Free Cash Flow (TTM) $29.95M $-81.54M aTyr Pharma Inc
1-Year Return 200.19% 119.02% aTyr Pharma Inc
Price-to-Sales Ratio (TTM) 2.65 N/A N/A
Enterprise Value $1.31B $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 3.38 N/A N/A
Gross Profit Margin (TTM) 98.13% N/A N/A
Revenue per Share (TTM) $24 $0 aTyr Pharma Inc
Earnings per Share (Diluted) $1.14 $-2.26 aTyr Pharma Inc
Beta (Stock Volatility) N/A 0.48 N/A
Short % of Float 9.90% 19.17% aTyr Pharma Inc

aTyr Pharma Inc vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

LIFE
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
aTyr Pharma Inc5.41%-1.44%-24.23%37.77%2,153.42%2,064.47%
Capricor Therapeutics Inc.3.57%2.14%-7.19%-12.57%0.64%-5.62%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
aTyr Pharma Inc200.19%537.14%246.89%457.50%-69.84%-64.02%
Capricor Therapeutics Inc.119.02%445.45%385.88%-42.15%-92.18%-98.04%

Performance & Financial Health Analysis: aTyr Pharma Inc vs Capricor Therapeutics Inc.

MetricLIFECAPR
Market Information
Market Cap i$1.03B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i497,145987,380
90 Day Avg. Volume i537,5651,234,213
Last Close$16.45$26.72
52 Week Range$0.64 - $32.50$4.30 - $40.37
% from 52W High-49.37%-33.81%
All-Time High$396.06 (Jun 01, 2015)$3,500.00 (Oct 22, 2007)
% from All-Time High-95.85%-99.24%
Growth Metrics
Quarterly Revenue Growth0.66%N/A
Quarterly Earnings Growth1.57%-1.00%
Financial Health
Profit Margin (TTM) i0.18%0.00%
Operating Margin (TTM) i0.22%0.00%
Return on Equity (TTM) i0.21%-0.47%
Debt to Equity (MRQ) i0.624.75
Cash & Liquidity
Book Value per Share (MRQ)$-1.45$5.33
Cash per Share (MRQ)$2.00$5.53
Operating Cash Flow (TTM) i$36.23M$-69,811,264
Levered Free Cash Flow (TTM) i$51.01M$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: aTyr Pharma Inc vs Capricor Therapeutics Inc.

MetricLIFE (Apr 24, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i14.35-15.61
Forward P/E i8.46-56.73
PEG Ratio i8.46-0.05
Price to Sales (TTM) i2.65N/A
Price to Book (MRQ) i-42.416.62
Market Capitalization
Market Capitalization i$1.03B$2.04B
Enterprise Value i$1.31B$1.72B
Enterprise Value Metrics
Enterprise to Revenue i3.38N/A
Enterprise to EBITDA i16.72-16.23
Risk & Other Metrics
Beta iN/A0.48
Book Value per Share (MRQ) i$-1.45$5.33

Financial Statements Comparison: aTyr Pharma Inc vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLIFE (2025)CAPR (2025)
Revenue/Sales i387.61M0
Cost of Goods Sold i6.73MN/A
COGS % of Revenue i1.7%-
Gross Profit i380.88MN/A
Gross Margin i98.3%-
Research & Development iN/A84.45M
Operating Income (EBIT) i72.92M-108.14M
Operating Margin i18.8%-
EBITDA i85.18M-106.21M
EBITDA Margin i22.0%-
Pre-Tax Income i75.74M-105.04M
Pre-Tax Income % of Revenue i19.5%-
Income Tax i4.59M1,600
Income Tax % of Revenue i1.2%-
Net Income (Profit) i71.15M-105.04M
Profit Margin i18.4%-

Balance Sheet & Liquidity Metrics

MetricLIFE (2025)CAPR (2025)
Cash & Equivalents i91.09M287.85M
Total Current Assets i245.80M322.94M
Total Current Assets % of Revenue i63.4%-
Total Current Liabilities i113.19M35.84M
Total Current Liabilities % of Revenue i29.2%-
Long-Term Debt i1.23M14.32M
Long-Term Debt % of Revenue i0.3%-
Total Shareholders Equity i-24.12M305.79M
Retained Earnings i-102.51M-304.88M
Retained Earnings % of Revenue i-26.4%-
Property, Plant & Equipment i2.32M22.27M

Cash Flow Statement Comparison

MetricLIFE (2025)CAPR (2025)
Operating Cash Flow i38.96M-71.86M
Operating Cash Flow % of Revenue i10.1%-
Capital Expenditures i-1.49M-11.72M
Free Cash Flow i29.95M-81.54M
FCF Margin i7.7%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLIFECAPR
Shares Short i2.26M10.04M
Short Ratio i4.297.73
Short % of Float i9.90%19.17%
Shares Outstanding i62.56M57.37M
Float Shares i25.92M48.61M
% Held by Insiders i6.31%9.47%
% Held by Institutions i23.87%53.91%
% Held by Public i69.82%36.62%

Dividend Analysis & Yield Comparison: aTyr Pharma Inc vs Capricor Therapeutics Inc.

MetricLIFECAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A